EBNK-001

N/A

Report date: 2026/02/25 20:02:36

Base Information

Drug NameEBNK-001
Drug Alias NameEBNK-001
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy
Mechanisms of ActionNatural killer cell replacements
TargetsUpdating
Therapy Area/IndicationsUrinary Bladder NeoplasmsKidney NeoplasmsLung Neoplasms +[14] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesEssen Biotech
China Registration ClassN/A

Develop Information

Active CompaniesEssen Biotech
Inactive CompaniesN/A
Active IndicationsUrinary Bladder NeoplasmsKidney NeoplasmsLung Neoplasms +[13] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A